LUMENHANCE
LOE ApproachingNDAORALFOR SOLUTION
Approved
Dec 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 6h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LUMENHANCE is an oral solution approved by NDA in 1997 by Bracco, a diagnostic or contrast agent delivered as a powder for solution. The mechanism of action and specific indications are not publicly detailed in available data, limiting assessment of therapeutic area.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100), signaling potential team consolidation or transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
No current job openings are linked to LUMENHANCE, reflecting its LOE-approaching status and mature lifecycle. Careers on this product focus on defending market position and managing transition rather than growth initiatives.
Brand ManagerCommercial Operations Analyst
Worked on LUMENHANCE at Bracco? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.